JUAN FLORES: Open Payments
NPI 1730550112 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,117 in 72 payments from 22 companies in 2025. Trend: 2023 $1,011 · 2024 $1,528 · 2025 $4,117
Food & beverage: $4,117
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 8 | $679 |
| Alkermes, Inc. | 6 | $419 |
| ABBVIE INC. | 6 | $313 |
| Vanda Pharmaceuticals Inc. | 6 | $306 |
| Novo Nordisk Inc | 5 | $304 |
| Teva Pharmaceuticals USA, Inc. | 8 | $240 |
| E.R. Squibb & Sons, L.L.C. | 2 | $187 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $174 |
| Gilead Sciences, Inc. | 2 | $154 |
| Insmed, Inc. | 1 | $150 |
Products named: Auvelity, LYBALVI, Wegovy, FANAPT, COBENFY, CAPLYTA, MAVYRET, Arikayce.
Industry payments across CA — which companies pay providers there.
